Template:Right ventricular myocardial infarction: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(7 intermediate revisions by 2 users not shown) | |||
Line 22: | Line 22: | ||
|- bgcolor="Pink" | |- bgcolor="Pink" | ||
! | ! | ||
[[ | [[ST elevation myocardial infarction pathophysiology|Pathophysiology]] | ||
|- | |- | ||
! | ! | ||
Line 142: | Line 142: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
Pharmacological Reperfusion | Pharmacological Reperfusion | ||
|- | |- | ||
! | ! | ||
Line 160: | Line 160: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
Mechanical Reperfusion | Mechanical Reperfusion | ||
|- | |- | ||
! | ! | ||
Line 166: | Line 166: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Door-to-Balloon|The Importance of Reducing Door-to-Balloon Times]] | |||
|- | |- | ||
! | ! | ||
Line 172: | Line 172: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
Antiplatelet therapy | :[[ST elevation myocardial infarction primary percutaneous coronary intervention|Primary PCI]] | ||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction percutaneous coronary intervention following fibrinolytic administration|Adjunctive and Rescue PCI]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction rescue percutaneous coronary intervention|Rescue PCI]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction facilitated percutaneous coronary intervention|Facilitated PCI]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST Elevation Myocardial Infarction Adjunctive Percutaneous Coronary Intervention|Adjunctive PCI]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction coronary artery bypass grafting|CABG]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction management of patients who were not reperfused|Management of Patients Who Were Not Reperfused]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction assessing success of reperfusion|Assessing Success of Reperfusion]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
Antithrombin Therapy | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy|Antithrombin Therapy]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Unfractionated Heparin|Unfractionated Heparin]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Enoxaparin|Low Molecular Weight Heparinoid Therapy]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Bivalirudin|Direct Thrombin Inhibitor Therapy]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Fondaparinux|Factor Xa Inhibition]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction deep vein thrombosis prophylaxis and anticoagulation|DVT Prophylaxis]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction deep vein thrombosis prophylaxis and anticoagulation|Long Term Anticoagulation]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
Antiplatelet Agents | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction aspirin therapy|Aspirin]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction thienopyridine therapy|Thienopyridine Therapy]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction glycoprotein IIbIIIa inhibition|Glycoprotein IIbIIIa Inhibition]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
Other Initial Therapy | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge|Inhibition of the Renin-Angiotensin-Aldosterone System]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction magnesium therapy|Magnesium Therapy]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction glucose control|Glucose Control]] | |||
|- | |||
! | |||
|- bgcolor="PaleTurquoise" | |||
! | |||
:[[ST elevation myocardial infarction calcium channel blocker therapy|Calcium Channel Blocker Therapy]] | |||
|- | |- | ||
! | ! |
Latest revision as of 18:15, 23 October 2012
Right ventricular myocardial infarction Microchapters |
Differentiating Right ventricular myocardial infarction from other Diseases |
---|
Diagnosis |
Treatment |
Pharmacological Reperfusion |
Mechanical Reperfusion |
Antithrombin Therapy |
Antiplatelet Agents |
Other Initial Therapy |
Right ventricular myocardial infarction On the Web |
Directions to Hospitals Treating Right ventricular myocardial infarction |
Risk calculators and risk factors for Right ventricular myocardial infarction |